Impact of tumor location and variables associated with overall survival in patients with colorectal cancer.

Wang, Cassia B.; Merchea, Amit; Shahjehan, Faisal; Colibaseanu, Dorin T.; Cochuyt, Jordan J.; Li, Zhuo; Kasi, Pashtoon Murtaza

doi:10.1200/jco.2018.36.15_suppl.e15651

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Studies have also shown that the tumors of rectum and left-sided colon are associated with increased survival compared to right-sided CRC, which is the result of the different embryologic origin of these parts of the gut. 29 We argue that these findings are more than hypothesis generating: younger individuals are at an increased risk of particularly rectal and left-sided colon cancers. This has implications for both screening modalities (eg, sigmoidoscopy) and treatment strategies.…”

Section: Discussionmentioning

confidence: 94%

Rising Proportion of Young Individuals With Rectal and Colon Cancer

Kasi

Shahjehan

Cochuyt

et al. 2019

Clinical Colorectal Cancer

Self Cite

113

View full text Add to dashboard Cite

We noticed an increased number of patients diagnosed with colorectal cancer (CRC) in their 20s, 30s, and 40s. We analyzed all CRC patients aged < 50 at our institutions from 1972 to 2017 and found increasing trends as well as a propensity for more distal location-findings that are hypothesis generating, given the embryologic origin of these tumors. This finding may have implications for screening guidelines. Background: Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being diagnosed with rectal and colon cancers at our institutions. Patients and Methods: This study included 3381 rectal and colon cancer patients from the Mayo Clinic cancer registry from 1972 to 2017 who were diagnosed with rectal or colon cancer and who were < 50 years old. Patient and cancer characteristics are described. The Cochran-Armitage trend test was used to see if the change in percentage diagnosed at age < 50 years had a significant trend over the years. A linear regression model was fit to estimate the percentage change per year when the trend was approximately linear. Results: The percentage of patients diagnosed with rectal or colon cancer in different age categories over the years showed a rising trend for individuals aged < 50. Most of these tumors were distal (rectum, left-sided colon, and rightsided colon were 49.8%, 28.8%, and 21.4%, respectively). This was more so for patients < 50 diagnosed with rectal cancer, which showed a linear increase at a rate of 0.26% per year (P < .001). Conclusion: Our study affirms the rising proportion of colorectal cancers found in young individuals, with a linear ongoing rise of rectal cancers in particular. This may have implications for the current screening recommendations for colorectal cancers, which are already being revised.

show abstract

Section: Discussionmentioning

confidence: 94%

Rising Proportion of Young Individuals With Rectal and Colon Cancer

Kasi

Shahjehan

Cochuyt

et al. 2019

Clinical Colorectal Cancer

Self Cite

113

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal cancers including CRC are heterogeneous in nature in terms of histology, presenting symptoms, progression, response to therapy, and outcomes that can lead to a difference in the management of various types of cancers (30). Tumor heterogeneity can be evaluated by measuring the wide-ranging levels of ctDNA and the identification of diverse patterns of mutations.…”

Section: Tumor Heterogeneity and Ctdnamentioning

confidence: 99%

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018

2019

Self Cite

View full text Add to dashboard Cite

Background: The promising aspect of circulating tumor DNA (ctDNA) is its rapid turnaround and non-invasive nature. According to the American Society of Clinical Oncology (ASCO) and College of American Pathologists joint ctDNA review published in March 2018, there is not sufficient evidence to support the use of ctDNA in practice for GI cancers. However, there were numerous studies presented at ASCO Annual Meeting supporting its value. We aimed to summarize on its role in the management of gastrointestinal cancers based on the studies presented recently, and future directions. Methods: We limited our search to keywords “ctDNA,” “circulating tumor DNA,” “cell-free DNA (cfDNA)” and/or “liquid biopsy,” at the 2018 ASCO Annual Meeting library abstracts and presentations. Results: There were 35 studies that revolved around ctDNA as a diagnostic tool, prognostic marker and/or a measure of tumor heterogeneity in gastrointestinal cancers. Depending on the assay used, the results of several studies showed that ctDNA was able to identify relevant mutations or fusions including RAS, HER2/Neu, BRAF, MET, BRCA2, APC, TP53, ALK, ROS1, PTEN , and NF1 . The prognosis in terms of tumor mutation burden, objective response rate, metastasis and survival were also estimated by various studies based on ctDNA. The findings showed that higher baseline ctDNA levels and/or increased number of mutations detected in ctDNA were associated with poor survival and multi-site metastasis. Right-sided colon cancer was associated with higher number of mutations in ctDNA than left-sided colon and rectal cancers. Similarly, tubular adenocarcinoma subtype of gastric cancer was more likely to have higher ctDNA levels than signet-ring cell subtype. The feasibility of assessing response to therapy and residual metastatic disease by using ctDNA which was otherwise not detected on imaging was also presented. Conclusions: The studies presented at ASCO 2018 report on the many ways ctDNA is of value in patients with gastrointestinal malignancies. Experts and discussants at the meeting argued that this may well indeed be ready for prime time for certain GI malignancies including colorectal cancers, especially in the metastatic setting. These findings alongside ongoing studies showing its feasibility into practice would likely lead to revision of the current guidelines for metastatic GI cancers.

show abstract

Sporadic pediatric colorectal carcinoma without known genetic predisposition - Defying the dictum

Agrawal

Garg

Babuta

et al. 2021

Indian Journal of Pathology and Microbiology

View full text Add to dashboard Cite

Pediatric colorectal carcinomas are extremely rare with an incidence of nearly 1.3 per million. Diagnosis is usually delayed following a lack of suspicion at this age. Increasing incidence as well as awareness provides an insight into the disease entity. Two cases of childhood colorectal carcinoma, one in an 11 and another in a 19-year-old boy are presented. However, they have been reparted to carry a forarable outcome. Both the cases showed mucin and signet ring cells which indicates an aggressive behavior. The presentation highlights the clinical characteristics and genetic implications in most of the patients. However, both our cases did not show any predisposing or genetic predisposition. These cases are presented to make aware the readers as to how the common dictum can be reversed and adolescents can also be affected by cancer, a disease of the elderly. Early diagnosis can provide a better management and prognosis.

show abstract

Impact of tumor location and variables associated with overall survival in patients with colorectal cancer.

Cited by 3 publications

References 0 publications

Rising Proportion of Young Individuals With Rectal and Colon Cancer

Rising Proportion of Young Individuals With Rectal and Colon Cancer

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018

Sporadic pediatric colorectal carcinoma without known genetic predisposition - Defying the dictum

Contact Info

Product

Resources

About